Bayer Guns For Top-Three Pharmaceutical Seat In China
This article was originally published in PharmAsia News
Greater China has been the fastest-growing region for Bayer HealthCare; its pharmaceutical business there increased 30 percent to achieve revenue of €1.8 billion in 2007 ($2.8 billion). The company attributes the success to its focus on OTC business. Generics, especially OTC drugs, will form the core of Bayer's growth in China after 2008 and it aims to be among the top three health care MNCs. However, some gaps need plugging: the firm has yet to launch in the country its top three blockbuster drugs, namely, Betaferon (interferon beta-1b), Yasmin (drospirenone/ethinyl estradiol) and Kogenate (recombinant clotting factor VIII). Bayer Schering Pharma plans to launch all its global heavyweights in China within three years and introduce over 20 new products within five years. (Click here for more - Chinese Language)
You may also be interested in...
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.